Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Argenx Se ADR
(NQ:
ARGX
)
463.41
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Argenx Se ADR
< Previous
1
2
3
4
5
6
7
Next >
Why Is European Drugmaker Argenx Stock Trading Higher On Monday?
June 24, 2024
The FDA has approved Argenx's Vyvgart Hytrulo for chronic inflammatory demyelinating polyneuropathy, with projections of $1.2 billion in U.S. revenues by 2030.
Via
Benzinga
Exposures
Product Safety
Argenx Surges After Its Bread-And-Butter Drug Wins Another FDA Approval
June 24, 2024
This is the second approval for the biotech company's drug, Vyvgart Hytrulo.
Via
Investor's Business Daily
Exposures
Product Safety
Micron To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Monday
June 24, 2024
Via
Benzinga
RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
June 24, 2024
Via
Benzinga
After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay
May 30, 2024
Immunovant, which jumped Wednesday on news from rival Biohaven, reversed course Thursday.
Via
Investor's Business Daily
Breaking Down argenx: 12 Analysts Share Their Views
May 10, 2024
Via
Benzinga
The Analyst Verdict: argenx In The Eyes Of 12 Experts
April 18, 2024
Via
Benzinga
Key Takeaways From argenx Analyst Ratings
March 26, 2024
Via
Benzinga
Biohaven Stock Stumbles As Protein-Degrading Drug Falls Short Of Expectations In Early-Stage Study
May 29, 2024
Biohaven shares drop as interim data from the Phase 1 study of BHV-1300 fell short of investor expectations.
Via
Benzinga
Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump
May 29, 2024
The company says it's still running additional testing of the drug, calling the results "positive."
Via
Investor's Business Daily
Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
May 09, 2024
Via
Benzinga
Earnings Scheduled For February 29, 2024
February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
Via
Benzinga
Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
May 09, 2024
Via
Benzinga
ARGX Stock Earnings: argenx Misses EPS, Misses Revenue for Q1 2024
May 09, 2024
ARGX stock results show that argenx missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Exact Sciences Reports Q1 Loss, Joins Beyond Meat, Duolingo And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
May 09, 2024
Via
Benzinga
Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy
April 10, 2024
Cartesian Therapeutics' autoimmune disease treatment with re-dosable mRNA CAR-Ts. Learn about Descartes-08, a promising anti-BCMA CAR-T therapy offering deeper, longer-lasting efficacy than current...
Via
Benzinga
Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday
March 26, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
March 21, 2024
Shares of FactSet Research Systems Inc. (NYSE: FDS) fell sharply during Thursday’s session after the company reported worse-than-expected second-quarter revenue and issued FY24 guidance.
Via
Benzinga
Guess? Posts Upbeat Earnings, Joins Lufax, Nortech Systems And Other Big Stocks Moving Higher On Thursday
March 21, 2024
U.S. stocks were higher, with the Dow Jones index gaining around 250 points on Thursday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is European Pharma Giant Argenx Valued At Over $20B Trading Higher On Thursday?
March 21, 2024
Argenx shares rise on Chugai's gMG trial disappointment. FDA-approved Vyvgart for anti-acetylcholine receptor antibody-positive adult patients. Enspryng's Phase 3 study results disappoint. Vyvgart...
Via
Benzinga
Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
March 21, 2024
Investors saw Chugai's experimental drug as a potential rival to Argenx's approved medicine, Vyvgart.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
March 21, 2024
Via
Benzinga
Why Micron Therapies Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
March 21, 2024
Shares of Micron Technology, Inc. (NASDAQ: MU) rose sharply in today’s pre-market trading as the company reported upbeat results for its second quarter and issued
Via
Benzinga
3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition
February 21, 2024
Now could be the time to start looking into these biotech stocks as there are imminent approvals on their clinical trials.
Via
InvestorPlace
New Hope For Patients With Chronic Autoimmune Conditions: Johnson & Johnson's Investigational Drug Meets Primary Goal In Two Studies
February 05, 2024
Johnson & Johnson's nipocalimab shows promise in Phase 3 VIVACITY for gMG & Phase 2 DAHLIAS for SjD. FDA-approved Vyvgart Hytrulo for gMG.
Via
Benzinga
Halozyme's Ambitious Five-Year Plan: Analysts Optimistic On Growth, Eyeing Market Expansion
January 18, 2024
Explore Halozyme Therapeutics' promising financial outlook up to 2028. Discover revenue forecasts, earnings projections, and market insights.
Via
Benzinga
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond
January 15, 2024
These five biotech companies could have a lot of room to run.
Via
The Motley Fool
Stock Market Rally Is In Merry Mood Heading Into Christmas Weekend: Weekly Review
December 22, 2023
Despite a Wednesday tumble, the major indexes are right at 2023 highs.
Via
Investor's Business Daily
Argenx's Autoimmune Trial Stumble: Analysts Cut Price Targets, Warn of Risky Outcomes
December 21, 2023
Wednesday, Argenx SE (NASDAQ: ARGX) released topline results from the ADDRESS Phase 3 study evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with pemphigus...
Via
Benzinga
Immunovant Scores Much-Needed Win Following Argenx-Led Sell-off
December 21, 2023
Immunovant reversed its fortunes Thursday following an Argenx-tied selloff Wednesday.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.